Is Wegovy Safe While Trying to Conceive?

The Short Answer: Stop Wegovy Before You Start Trying

The FDA label for Wegovy states directly that the drug should be discontinued at least two months before a planned pregnancy based on the drug's elimination half-life of approximately one week and the precautionary principle applied to embryo-fetal safety. This is not a soft suggestion. Animal reproductive toxicology studies showed dose-dependent fetal harm, and there are no adequate, well-controlled studies in pregnant women to contradict or reassure against those findings.

The practical implication: if you are actively trying to conceive right now and you are on Wegovy, stop the medication, speak with your prescriber, and give yourself that two-month window before unprotected sex begins.

Why the Two-Month Window Exists

Semaglutide has an elimination half-life of approximately 6 to 7 days. Full systemic clearance takes roughly five half-lives, meaning the drug is substantially gone from your body within five to six weeks. The FDA chose a two-month (approximately eight-week) washout period to provide a safety margin beyond those five half-lives, accounting for individual pharmacokinetic variability. A woman who ovulates on cycle day 14 and conceives in month one of trying would have a semaglutide-free system before implantation if she stopped two months prior.

What "Not Recommended" Actually Means Clinically

Some drug labels say "avoid if possible." Wegovy's language is more directive. The prescribing information advises discontinuation at least two months before a planned pregnancy specifically because of animal data showing fetal structural malformations and growth restriction. Until human data accumulate through the ongoing Novo Nordisk pregnancy registry, extrapolation from animal studies is all clinicians have, and those studies are concerning enough to recommend a clean break.

What Animal Studies Actually Found (and Why They Matter)

Animal reproductive toxicology is not perfect human data, but it is the foundation of every drug pregnancy safety rating. For semaglutide, the findings are worth understanding in detail rather than glossing over.

Rodent and Rabbit Studies

In rat and rabbit embryo-fetal development studies, semaglutide produced fetal structural abnormalities, reduced fetal body weight, and increased early embryonic deaths at exposures that were below or comparable to the human clinical exposure at 2.4 mg weekly. Specific malformations included skeletal defects and alterations in major blood vessel development. These occurred at doses that produced systemic exposures lower than what a woman taking 2.4 mg weekly would carry.

The mechanism is thought to involve GLP-1 receptor activation in developing fetal tissues. GLP-1 receptors are expressed in the embryo during organogenesis, meaning the period from roughly weeks 3 to 8 of human pregnancy when organ systems form. This is also, critically, the period when many women do not yet know they are pregnant.

The Clinical Exposure Overlap Problem

Here is what makes the animal data clinically uncomfortable: the harmful exposures in animals were not pharmacologically exotic doses. They were within the range of what human clinical doses achieve. That overlap is the core reason regulatory agencies around the world, including the FDA, Health Canada, and the EMA, all recommend against use in pregnancy.

Human Data: What We Know and Do Not Know

As of early 2025, no randomized controlled trial data exist on semaglutide 2.4 mg in pregnant women, and none will exist in the foreseeable future because enrolling pregnant participants in a weight-loss drug trial is neither ethical nor feasible. What exists is:

Case reports and spontaneous reports. A small number of inadvertent pregnancy exposures have been reported through pharmacovigilance systems, but sample sizes are far too small to draw conclusions about malformation rates or pregnancy outcomes.

Manufacturer pregnancy registry. Novo Nordisk operates a pregnancy exposure registry for women who take Ozempic or Wegovy and become pregnant. As of 2025, this registry is actively recruiting but has not published outcome data sufficient for safety conclusions.

Extrapolation from metformin and other metabolic drugs. Some clinicians compare GLP-1 receptor agonists to older metabolic drugs with longer pregnancy data records, but this comparison is mechanistically weak. Semaglutide crosses the placenta and has direct GLP-1 receptor binding activity in fetal tissue in ways that metformin, a small-molecule organic acid, does not replicate.

This is an honest evidence gap. The data women and clinicians need simply do not exist yet. Anyone claiming Wegovy is "probably fine" in early pregnancy is extrapolating well beyond available evidence.

The PCOS Connection: Fertility Goes Up, Risk Goes Up

For women with polycystic ovary syndrome, Wegovy adds a layer of complexity that many prescribers do not address explicitly: the drug may restore ovulation.

PCOS affects 6 to 12 percent of reproductive-age women and is one of the most common causes of anovulatory infertility. Women with PCOS and obesity often have irregular or absent cycles. Weight loss of 5 to 10 percent of body weight restores spontaneous ovulation in a meaningful proportion of these women, and semaglutide-driven weight loss can achieve that threshold within the first 12 to 20 weeks of treatment.

What This Means for You If You Have PCOS

If you have PCOS, you may have been using irregular cycles as implicit contraception. Once Wegovy begins working and your cycle regularizes, that assumption fails. Women with PCOS on GLP-1 receptor agonists who are not ready for pregnancy need effective contraception throughout treatment.

Conversely, if you have PCOS and are trying to conceive, the weight loss Wegovy produces before you stop the drug may genuinely improve your chances. A 2022 analysis in Fertility and Sterility found that GLP-1 receptor agonist treatment was associated with improved ovulation rates and reduced androgen levels in women with PCOS. The strategy, then, may be: use Wegovy to achieve meaningful weight loss, stop it two months before you begin trying, and carry that metabolic benefit into your conception attempt.

GLP-1 Physiology Across the Menstrual Cycle and Reproductive Life

GLP-1 receptor agonists interact with female reproductive physiology in ways that go beyond weight loss.

Cycle-Phase Pharmacokinetics

Subcutaneous drug absorption can vary modestly across the menstrual cycle due to changes in skin blood flow and subcutaneous adipose tissue perfusion driven by estrogen and progesterone. This effect has been documented for insulin and is theorized to apply to other subcutaneous injectables, but direct pharmacokinetic studies of semaglutide across menstrual cycle phases have not been published as of 2025. This is an area where women have been under-represented in pharmacokinetic research.

Nausea, Hormones, and Cycle Timing

Semaglutide's most common side effects, nausea and vomiting, overlap with early pregnancy symptoms. A woman who has recently stopped Wegovy and conceives may find it difficult to distinguish drug washout nausea from morning sickness. Pregnancy testing early in any missed cycle is advisable for women who stopped Wegovy within the past two to three months.

Perimenopause and Weight Management Context

Women in perimenopause often experience accelerating weight gain, particularly central adiposity, driven by declining estrogen. Wegovy is approved for women in this life stage. If a perimenopausal woman retains any possibility of pregnancy (which persists until 12 consecutive months of amenorrhea have passed), the same contraindication applies. Contraception remains necessary until confirmed post-menopause.

Pregnancy and Lactation Safety: The Mandatory Clinical Summary

Pregnancy

The FDA prescribing information for Wegovy places semaglutide in the category of drugs with animal data showing risk and insufficient human data. The label states: "Based on animal reproduction studies, there may be risks to the fetus from exposure to semaglutide during pregnancy." This language is notable because it is not a generic precautionary statement. It is anchored in specific animal findings.

Key pregnancy safety facts:

• Stop Wegovy at least 2 months before planned conception
• If you become pregnant while taking Wegovy, stop the drug immediately and contact your obstetric provider
• Report inadvertent pregnancy exposure to the Novo Nordisk registry at 1-800-727-6500
• Gestational weight management during pregnancy should follow ACOG guidance on gestational weight gain, not GLP-1 pharmacotherapy

Lactation

Semaglutide's transfer into human breast milk is unknown. The molecular weight of semaglutide is approximately 4,114 daltons, which is large enough that transfer into milk is expected to be limited, but no published human lactation pharmacokinetic data exist. Because transfer cannot be ruled out and because the effects of GLP-1 receptor agonists on a nursing infant's developing gastrointestinal and endocrine systems are unknown, breastfeeding while taking Wegovy is not recommended.

The NIH LactMed database notes that "because of the lack of data, an alternate drug may be preferred, especially while nursing a newborn or preterm infant." For a woman who has lost significant weight on Wegovy and wants to restart postpartum, the practical guidance is: complete breastfeeding before restarting, or choose a different weight management strategy during lactation.

Contraception Requirements

Any woman of reproductive potential who is taking Wegovy and not actively trying to conceive needs effective contraception. This is not optional. The drug is teratogenic in animals at clinically relevant exposures, and oral hormonal contraceptives may have modestly reduced absorption around the time of Wegovy injections due to delayed gastric emptying. Long-acting reversible contraception, specifically an IUD or subdermal implant, avoids this interaction entirely and is the preferred option for women on GLP-1 receptor agonists who want reliable pregnancy prevention.

Who This Is Right For and Who Should Not Use It (Framed by Life Stage)

Reproductive Years: Not Trying to Conceive

Wegovy is appropriate for women in their reproductive years who meet the FDA-approved indications: a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Reliable contraception is non-negotiable throughout treatment.

Reproductive Years: Planning Pregnancy in the Future

This is arguably the best-fit scenario for a structured Wegovy course. A woman who wants to conceive in 12 to 24 months can use Wegovy to achieve meaningful weight loss, stop the drug two months before she begins trying, and carry the metabolic improvements (improved insulin sensitivity, lower androgen levels in PCOS, reduced central adiposity) into the periconception period. Weight loss of 10 percent or more before pregnancy is associated with improved IVF outcomes in women with obesity.

Trying to Conceive Now

Stop Wegovy immediately. Do not use it while actively trying to conceive. Discuss with your clinician whether alternative ovulation-supporting interventions, including letrozole for PCOS-related anovulation or lifestyle modifications, are appropriate bridges.

Pregnant

Do not use Wegovy. Stop it immediately if pregnancy is discovered. Nutrition, appropriate gestational weight gain, and prenatal care are the evidence-based approach to weight management during pregnancy.

Postpartum and Breastfeeding

Do not restart Wegovy while breastfeeding. Once breastfeeding has stopped and your clinician confirms it is appropriate, Wegovy may be restarted for postpartum weight management.

Perimenopause and Post-Menopause

Wegovy may be used in these life stages without contraception concerns after confirmed post-menopause (12 consecutive months of amenorrhea). The drug's weight loss and metabolic benefits are relevant to this life stage, and there is no reproductive safety concern once fertility has ended.

What Happens to Your Weight When You Stop Wegovy

This is a practical concern every woman planning pregnancy should address with her clinician. The STEP 4 trial showed that participants who discontinued semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight within one year. Weight regain after stopping is the expected pattern, not an exception.

For a woman trying to conceive, this means:

1. Set a realistic weight goal before stopping, knowing some regain will occur during the two-month washout and early pregnancy.
2. Transition to behavioral and dietary strategies that can continue through pregnancy.
3. Work with a registered dietitian who specializes in perinatal nutrition to maintain as much metabolic benefit as possible.

The goal is not to arrive at your lowest Wegovy weight at conception. It is to arrive at a weight that supports a healthy pregnancy, and to do so without the drug in your system.

Questions to Ask Your Clinician Before You Stop Wegovy

The stop date is not the only decision point. Before you discontinue:

• What weight loss goal should I reach before stopping?
• Do I need a contraception change before stopping (particularly if I was relying on oral contraceptives)?
• Should I see a maternal-fetal medicine specialist or reproductive endocrinologist given my weight history and fertility goals?
• What prenatal vitamins should I start now, and do I need higher-dose folic acid given my BMI? Women with obesity are advised by ACOG to take 4 mg of folic acid daily in the periconception period, compared to the standard 400 to 800 micrograms for women at average risk.
• If I have PCOS, do I need cycle monitoring or ovulation induction support once Wegovy is stopped?

FAQ